Enveric Biosciences Faces Delisting Notice

Ticker: ENVB · Form: 8-K · Filed: May 23, 2024 · CIK: 890821

Enveric Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyEnveric Biosciences, Inc. (ENVB)
Form Type8-K
Filed DateMay 23, 2024
Risk Levelhigh
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $6,481,856
Sentimentbearish

Sentiment: bearish

Topics: delisting, compliance, listing-standards

TL;DR

Enveric Biosciences got a notice about potentially being delisted.

AI Summary

Enveric Biosciences, Inc. filed an 8-K on May 23, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in Naples, Florida, and its fiscal year ends on December 31st.

Why It Matters

This filing indicates potential issues with Enveric Biosciences' compliance with stock exchange listing standards, which could lead to the company's shares being delisted.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading viability.

Key Players & Entities

  • Enveric Biosciences, Inc. (company) — Registrant
  • May 23, 2024 (date) — Filing Date
  • May 21, 2024 (date) — Date of earliest event reported
  • Naples, FL (location) — Principal executive offices

FAQ

What is the specific reason for Enveric Biosciences' notice of delisting?

The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard', but the specific rule or standard is not detailed in this excerpt.

When was this 8-K filing submitted?

The filing was submitted on May 23, 2024.

What is the earliest event date reported in this filing?

The earliest event date reported is May 21, 2024.

Where are Enveric Biosciences' principal executive offices located?

The principal executive offices are located at 4851 Tamiami Trail N, Suite 200, Naples, FL 34103.

What is the company's SIC code?

The Standard Industrial Classification (SIC) code for Enveric Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 781 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-05-23 08:00:29

Key Financial Figures

  • $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
  • $6,481,856 — olders' equity as of March 31, 2024 was $6,481,856. Receipt of the Minimum Stockholders'

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 23, 2024 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker, Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.